Compare RVSN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | CALC |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Israel | United States |
| Employees | 47 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | RVSN | CALC |
|---|---|---|
| Price | $4.55 | $0.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 16.2K | ★ 1.0M |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.46 |
| 52 Week High | $9.39 | $7.20 |
| Indicator | RVSN | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 44.77 |
| Support Level | $4.60 | $0.52 |
| Resistance Level | $5.09 | $0.93 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 51.03 | 36.20 |
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.